tbuckley/cabot-search huggingface dataset:
Associations between morning–evening chronotype, fatigue, and QOL in breast cancer survivors.
Authors: Oxana Palesh, M. Melissa Packer, Holly George, Cheryl Koopman, Pasquale F. Innominato
Journal: Journal of Clinical Oncology (2016)

246 Background: Emerging evidence suggests that circadian disruption is associated with cancer and cancer treatments. Chronotype is defined as a behaviorally manifested preference for a certain timing of sleep and activity. Previous studies have revealed that living out of sync from one’s innate chronotype can have detrimental effects on one’s health. Although there has been research examining the associations between chronotype and health, not much is known about the relationship between chronotype, fatigue, and QOL in cancer survivors. Methods: 68 Breast cancer survivors completed questionnaires to assess their chronotype (Horne-Ostberg), to rate their fatigue (MDASI), and to evaluate their QOL (FACIT). The Horne-Ostberg questionnaire yields a range of values indicating survivors’ preference for early or late activity. The study sample was divided by terciles according to survivors’ “morningness” or “eveningness” preferences (i.e., chronotypes). Results: Morning chronotype was associated with significantly less severe tiredness and drowsiness as well as significantly better physical well-being and fatigue subscale scores as compared to evening chronotype. Tiredness median (M) scores were highest for evening chronotype (M=5.5), moderate for mid-range chronotype (M=4.5), and lowest for morning chronotype (M=3.0), a significant difference (p=0.046). Drowsiness scores were highest for evening chronotype (median=6.0), moderate for mid-range chronotype (M=4.0), and lowest for morning chronotype (M=3.0), p=0.046. The median score for physical well-being was significantly lower for evening compared to morning chronotypes (22.5 vs. 25.0, p=0.038) and morning types reported significantly better health in respect to fatigue compared to evening types (40.5 vs. 35.5, p=0.045). Conclusions: Survivors with early chronotype (early to bed, early to rise) reported less fatigue, drowsiness, and better overall physical well-being. While chronotype is believed to be genetically driven, certain behavioral, pharmacological, and bright light modifications can be used to help patients shift their circadian rhythm towards earlier morning type and may experience improvements in physical well-being.
Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.
Authors: Andre Baruchel, Marie-Françoise Auclerc, Yves Perel, Françoise Mechinaud, Anne Auvrignon, Claudine Schmitt, Christophe Piguet, Odile Lejars, Christian Berthou, François Demeocq, Pascale Schneider, Virginie Gandemer, Gérard Michel, Jean-Michel Cayuela, Thierry Leblanc, Guy Leverger
Journal: Blood (2006)
Feasibility and acceptability of integrated cardiac rehabilitation in outpatients referred for autologous bone marrow transplantation.
Authors: Edith Pituskin, Derek Rothe, Nanette Cox-Kennett, Gabor Gyenes, Ian Paterson, Irwindeep Sandhu, Chris Venner
Journal: Journal of Clinical Oncology (2016)

139 Background: High-dose chemotherapy (HDCT) and bone marrow/hematopoietic cell transplantation (BMT) is established therapy for many malignancies. While advances in transplant practise have led to improved cancer-specific outcomes, HDCT negatively impacts healthy organ function via direct effects (ie high-dose cytotoxic injury to organ systems) and indirect effects (i.e., functional disability). The resulting cardiometabolic sequelae such as dyslipidemia, hypertension, diabetes, and weight gain (with lean body mass loss) contribute to the significantly increased rates of cardiovascular (CV) mortality and heart failure (HF) observed in HDCT survivors. Cardiac rehabilitation/secondary prevention (CR/SP) programs are a level 1 recommendation in multiple CV diseases, reducing CV risk and events. Currently, the feasibility of integrating standard CR/SP programs in outpatients (PTS) referred for HDCT is unknown. Aim: To prospectively evaluate feasibility and acceptability of routine referral tocardiovascular rehabilitation/secondary prevention (CR/SP) in unselected lymphoma PTSreferred for autologous HDCT/BMT. Methods: Lymphoma PTS referred for HDCT/BMT were screened and referred to the CR/SP program. Baseline exercise testing was performed prior to HDCT/BMT. Upon recovery (6 weeks) testing was repeated, and PTS were invited to participate in a 6-week standard CR/SP program of exercise rehabilitation and CV risk reduction education. Results: 20 PTS were referred for HDCT/BMT from January 1, 2015 to July 1, 2015. All were referred to the CR/SP program. 100% underwent exercise testing, and all proceeded to BMT without adverse cardiovascular outcomes or mortality. High levels of satisfaction of CR/SP program components were reported. Conclusions: In unselected PTS, seamless integration of CR/SP within standard HDCT/BMT care is feasible and acceptable. We expect short term measurable impacts including reduced symptom burden and improved quality of life. Longer term impacts will evaluate CV morbidity and mortality. This work will inform patient-centered care and improve supportive and survivorship care across the cancer continuum.
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry
Authors: Carlos Fernández Carrillo, Sabela Lens, Elba Llop, Juan Manuel Pascasio, Javier Crespo, Juan Arenas, Inmaculada Fernández, Carme Baliellas, José Antonio Carrión, Manuel de la Mata, Maria Buti, Lluís Castells, Agustín Albillos, Manuel Romero, Juan Turnes, Clara Pons, José María Moreno‐Planas, José Javier Moreno‐Palomares, Conrado Fernández‐Rodriguez, Javier García‐Samaniego, Martín Prieto, Miguel Fernández Bermejo, Javier Salmerón, Ester Badia, Magdalena Salcedo, José Ignacio Herrero, Rafael Granados, Michel Blé, Zoe Mariño, José Luis Calleja
Journal: Hepatology (2017)

Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, noninterventional, national, multicenter study in patients from the Spanish Hepa-C registry investigated the effectiveness and safety of interferon-free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered). Patients transplanted during treatment or within 12 weeks of completing treatment were excluded. Among 843 patients with cirrhosis (Child-Turcotte-Pugh [CTP] class A, n = 564; CTP class B/C, n = 175), 90% achieved sustained virologic response 12 weeks after treatment (SVR12). Significant differences in SVR12 and relapse rates were observed between CTP class A and CTP class B/C patients (94% versus 78%, and 4% versus 14%, respectively; both P < 0.001). Serious adverse events (SAEs) were more common in CTP class B/C versus CTP class A patients (50% versus 12%, respectively; P < 0.001). Incident decompensation was the most common serious adverse event (7% overall). Death rate during the study period was 16/843 (2%), significantly higher among CTP class B/C versus CTP class A patients (6.4% versus 0.9%; P < 0.001). Baseline Model for End-Stage Liver Disease (MELD) score alone (cut-off 18) was the best predictor of survival.Patients with decompensated cirrhosis receiving DAAs present lower response rates and experience more SAEs. In this setting, a MELD score ≥18 may help clinicians to identify those patients with a higher risk of complications and to individualize treatment decisions. (Hepatology 2017;65:1810-1822).
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
Authors: S. Stacchiotti, A. Gronchi, P. Fossati, T. Akiyama, C. Alapetite, M. Baumann, J.Y. Blay, S. Bolle, S. Boriani, P. Bruzzi, R. Capanna, A. Caraceni, R. Casadei, V. Colia, J. Debus, T. Delaney, A. Desai, P. Dileo, S. Dijkstra, F. Doglietto, A. Flanagan, S. Froelich, P.A. Gardner, H. Gelderblom, Z.L. Gokaslan, R. Haas, C. Heery, N. Hindi, P. Hohenberger, F. Hornicek, R. Imai, L. Jeys, R.L. Jones, B. Kasper, A. Kawai, M. Krengli, A. Leithner, I. Logowska, J. Martin Broto, D. Mazzatenta, C. Morosi, P. Nicolai, O.J. Norum, S. Patel, N. Penel, P. Picci, S. Pilotti, S. Radaelli, F. Ricchini, P. Rutkowski, S. Scheipl, C. Sen, E. Tamborini, K.A. Thornton, B. Timmermann, V. Torri, P.U. Tunn, M. Uhl, Y. Yamada, D.C. Weber, D. Vanel, P.P. Varga, C.L.A. Vleggeert-Lankamp, P.G. Casali, J. Sommer
Journal: Annals of Oncology (2017)

Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, resulting in inconsistent care and suboptimal outcomes for many patients. To address this shortcoming, the European Society of Medical Oncology (ESMO) and the Chordoma Foundation, the global chordoma patient advocacy group, convened a multi-disciplinary group of chordoma specialists to define by consensus evidence-based best practices for the optimal approach to chordoma. In January 2015, the first recommendations of this group were published, covering the management of primary and metastatic chordomas. Additional evidence and further discussion were needed to develop recommendations about the management of local-regional failures. Thus, ESMO and CF convened a second consensus group meeting in November 2015 to address the treatment of locally relapsed chordoma. This meeting involved over 60 specialists from Europe, the United States and Japan with expertise in treatment of patients with chordoma. The consensus achieved during that meeting is the subject of the present publication and complements the recommendations of the first position paper.
In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study
Authors: Youn H. Kim, Dita Gratzinger, Cameron Harrison, Joshua Brody, Debra Czerwinski, Leon Xing, Anjali Morales, Weiyun Ai, Farah Abdulla, Daniel Navi, Robert J. Tibshirani, Ranjana Advani, Yasodha Natkunam, Richard T. Hoppe, Ron Levy
Journal: Blood (2010)
RARE-65. DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMORS: 13 CASES OF A RARE CONDITION
Authors: Jill Goslinga, Corey Gill, Tracy Batchelor
Journal: Neuro-Oncology (2016)

This report will summarize key clinical features of thirteen cases of dysembryoplastic neuroepithelial tumor (DNET), a rare brain tumor that can cause intractable seizures. Thirteen cases of DNET were identified from patient records at the Massachusetts General Hospital Brain Tumor Center. Key clinical features were extracted from each patient’s record for this summary report. The study database is approved by the institutional IRB. Among the thirteen cases identified, 9 patients were female and 4 were male; median age at diagnosis was 39.2 years (range 24.3 - 68.4). Initial symptoms at presentation were most commonly seizures (n=11) and rarely sensory changes (n=1); one case discovered incidentally was asymptomatic at diagnosis. Radiographic appearance was most commonly T1 non-enhancing (n=8) and T2 hyperintense (n=9), but three cases were T1 enhancing. Tumor location was most commonly temporal (n=10) and less commonly frontal (n=2) or parietal (n=1). Nearly all patients were treated with gross total resection (GTR, n=12) but one patient received subtotal resection (STR, n=1). After surgical treatment, nearly all patients were progression-free (n=12), but one case of progression resulted in repeat surgery 4 months after initial surgery (n=1). Key post-surgical neurological deficits included seizures (n=2), memory deficits (n=2), and weakness (n=1); 5 patients were neurologically asymptomatic post-surgery, and post-surgical deficits were unknown in 3 of 13 patients. Median patient follow-up duration was 5.2 years (range 0.67 to 17.0 years) and no deaths were reported. This case series highlights key clinical themes in DNET cases as well as clinical areas of uncertainty. As previously reported, the most common presenting symptom was seizure, and the most common radiographic appearance was T1 non-enhancing, T2 hyperintense. Most tumors were located in the temporal lobe, and 12/13 patients were treated with gross total resection. Only one patient required repeat surgery for recurrence.
Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy
Authors: Masayasu Naito, Ursula Hainz, Kristen Stevenson, Anselmo Alonso, Ken-ichi Matsuoka, Tesuro Sasada, Donna Neuberg, Jerome Ritz, Gordon J. Freeman, Catherine J Wu
Journal: Blood (2011)
EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
Authors: M. Nishio, T.S.K. Mok, K. Nakagawa, N. Yamamoto, Y.-K. Shi, L. Zhang, S. Lu, R. Soo, J. Yang, S. Morita, S. Sugawara, H. Nokihara, T. Takahashi, K. Goto, J. Chang, M. Maemondo, Y. Ichinose, Y. Cheng, W.-T. Lim, T. Tamura
Journal: Annals of Oncology (2016)
Anti–Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients
Authors: M. Kristen Demoruelle, Kylie K. Harrall, Linh Ho, Monica M. Purmalek, Nickie L. Seto, Heather M. Rothfuss, Michael H. Weisman, Joshua J. Solomon, Aryeh Fischer, Yuko Okamoto, Lindsay B. Kelmenson, Mark C. Parish, Marie Feser, Chelsie Fleischer, Courtney Anderson, Michael Mahler, Jill M. Norris, Mariana J. Kaplan, Brian D. Cherrington, V. Michael Holers, Kevin D. Deane
Journal: Arthritis & Rheumatology (2017)

Studies suggest that rheumatoid arthritis (RA)-related autoimmunity is initiated at a mucosal site. However, the factors associated with the mucosal generation of this autoimmunity are unknown, especially in individuals who are at risk of future RA. Therefore, we tested anti-cyclic citrullinated peptide (anti-CCP) antibodies in the sputum of RA-free first-degree relatives (FDRs) of RA patients and patients with classifiable RA.We evaluated induced sputum and serum samples from 67 FDRs and 20 RA patients for IgA anti-CCP and IgG anti-CCP, with cutoff levels for positivity determined in a control population. Sputum was also evaluated for cell counts, neutrophil extracellular traps (NETs) using sandwich enzyme-linked immunosorbent assays for protein/nucleic acid complexes, and total citrulline.Sputum was positive for IgA and/or IgG anti-CCP in 14 of 20 RA patients (70%) and 17 of 67 FDRs (25%), including a portion of FDRs who were serum anti-CCP negative. In the FDRs, elevations of sputum IgA and IgG anti-CCP were associated with elevated sputum cell counts and NET levels. IgA anti-CCP was associated with ever smoking and with elevated sputum citrulline levels.Anti-CCP is elevated in the sputum of FDRs, including seronegative FDRs, suggesting that the lung may be a site of anti-CCP generation in this population. The association of anti-CCP with elevated cell counts and NET levels in FDRs supports a hypothesis that local airway inflammation and NET formation may drive anti-CCP production in the lung and may promote the early stages of RA development. Longitudinal studies are needed to follow the evolution of these processes relative to the development of systemic autoimmunity and articular RA.
A Biomathematical Analysis of Immunophenotypic Characteristics in Patients with Acute Myeloblastic Leukemia.
Authors: Adriana Plesa, Gabriela Ciuperca, Stephane Genieys, Veronique Louvet, Laurent Pujo-Menjouet, Arnaud Millaret, Charles Dumontet, Vitaly Volpert
Journal: Blood (2006)
Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older
Authors: Michelle C. Odden, Carmen A. Peralta, Dan R. Berlowitz, Karen C. Johnson, Jeffrey Whittle, Dalane W. Kitzman, Srinivasan Beddhu, John W. Nord, Vasilios Papademetriou, Jeff D. Williamson, Nicholas M. Pajewski
Journal: JAMA Internal Medicine (2017)

Intensive blood pressure (BP) control confers a benefit on cardiovascular morbidity and mortality; whether it affects physical function outcomes is unknown.To examine the effect of intensive BP control on changes in gait speed and mobility status.This randomized, clinical trial included 2636 individuals 75 years or older with hypertension and no history of type 2 diabetes or stroke who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). Data were collected from November 8, 2010, to December 1, 2015. Analysis was based on intention to treat.Participants were randomized to intensive treatment with a systolic BP target of less than 120 mm Hg (n = 1317) vs standard treatment with a BP target of less than 140 mm Hg (n = 1319).Gait speed was measured using a 4-m walk test. Self-reported information concerning mobility was obtained from items on the Veterans RAND 12-Item Health Survey and the EQ-5D. Mobility limitation was defined as a gait speed less than 0.6 meters per second (m/s) or self-reported limitations in walking and climbing stairs.Among the 2629 participants in whom mobility status could be defined (996 women [37.9%]; 1633 men [62.1%]; mean [SD] age, 79.9 [4.0] years), median (interquartile range) follow-up was 3 (2-3) years. No difference in mean gait speed decline was noted between the intensive- and standard-treatment groups (mean difference, 0.0004 m/s per year; 95% CI, -0.005 to 0.005; P = .88). No evidence of any treatment group differences in subgroups defined by age, sex, race or ethnicity, baseline systolic BP, chronic kidney disease, or a history of cardiovascular disease were found. A modest interaction was found for the Veterans RAND 12-Item Health Survey Physical Component Summary score, although the effect did not reach statistical significance in either subgroup, with mean differences of 0.004 (95% CI, -0.002 to 0.010) m/s per year among those with scores of at least 40 and -0.008 (95% CI, -0.016 to 0.001) m/s per year among those with scores less than 40 (P = .03 for interaction). Multistate models allowing for the competing risk of death demonstrated no effect of intensive treatment on transitions to mobility limitation (hazard ratio, 1.06; 95% CI, 0.92-1.22).Among adults 75 years or older in SPRINT, treating to a systolic BP target of less than 120 mm Hg compared with a target of less than 140 mm Hg had no effect on changes in gait speed and was not associated with changes in mobility limitation.clinicaltrials.gov Identifier: NCT01206062.
Treatment of eosinophilic gastritis by epicutaneous immunotherapy (EPIT) in peanut allergic piglets
Authors: Lucie Mondoulet, Nicolas Kalach, Véronique Dhelft, Thibaut Larcher, Carine Delayre-Orthez, Hugh A. Sampson, Pierre-Henri Benhamou, Christophe M. Dupont
Journal: Journal of Allergy and Clinical Immunology (2017)
Laboratory HIT Testing in Critically Ill Patients
Authors: Mark A. Crowther, Stephan Langevin, Jamie L Cooper, Peter Dodek, John Muscedere, Martin Albert, Kosar Khwaja, Jim Kutsiogiannis, Geeta Mehta, James Klinger, Jan Friedrich, Lauralyn McIntyre, Marlies Ostermann, Gordon Guyatt, Nicole Zytaruk, Diane Heels-Ansdell, Jo-Ann Sheppard, Deborah J Cook, Theodore E. Warkentin
Journal: Blood (2011)
Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer.
Authors: A. Takagane, H. Takiuchi, K. Ikejiri, I. Mochizuki, H. Mochizuki, K. Kotake, S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, Y. Matsubara, K. Sugihara
Journal: Journal of Clinical Oncology (2011)

3561 Background: The ACTS-CC trial is a phase III trial designed to validate non-inferiority of S-1 to UFT/ LV, a standard treatment in Japan as adjuvant chemotherapy for stage III colon cancer. We report the results of an interim analysis of safety of these treatments in this trial. Methods: Patients with stage III colon cancer and a PS of 0-1 who underwent curative surgery were randomly assigned to receive UFT/LV (UFT: 300 to 600 mg/day according to BSA and, LV: 75 mg/day on days 1 to 28, followed by 7 days rest, 5 courses) or S-1 (80, 100, or 120 mg/day according to BSA on days 1 to 28, followed by 14 days rest, 4 courses). We analyzed clinicopathological features, treatment status and safety. Results: Among 1,535 enrolled patients between Apr. 2009 and Jun. 2010, we excluded 31 patients who had duplicate registration, withdrew informed consent, or did not receive the assigned treatment. 1,504 patients (756 in S-1 group, 748 in UFT/LV group) were included in this analysis. Totally, the mean age at enrollment was 64.5 years, the male:female ratio was 1.2:1, wide lymph node dissection (D3) was done in 80% and the median number of dissected lymph nodes was 17. The completion rate of the protocol treatment was 75% (77% in S-1 group, 73% in UFT/LV group), and 18% of patients discontinued treatment within 2 courses. Treatment was discontinued because of adverse events (AEs) in 18% (18% in S-1 group, 18% in UFT/LV group). The mean dose intensity (actual cumulative dose received/total dose according to the protocol) was 82% in S-1 group and 81% in UFT/LV group, including the patients who discontinued treatment because of recurrence. The overall incidences of AEs in S-1 group and UFT/LV group were 80% and 74%: 33% and 27% for anemia, 32% and 25% for anorexia, 27% and 13% for pigmentation, 26% and 23% for hyperbilirubinemia, 23% and 24% for diarrhea, 19% and 14% for stomatitis, 15% and 20% for AST, and 13% and 21% for ALT, respectively. Conclusions: Although AE profiles differed between S-1 group and UFT/LV group in this trial, AEs were acceptable, and the completion rate of the protocol treatment was high. Both S-1 and UFT/LV could be safely used as adjuvant therapy.